TD Cowen raised the firm’s price target on Avidity Biosciences (RNA) to $78 from $56 and keeps a Buy rating on the shares. The firm updated its model and corresponding estimates in conjunction with its Q3 earnings preview.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity announces FDA removed partial clinical hold on Delpacibart Etedesiran
- Biotech Alert: Searches spiking for these stocks today
- 3 Best Stocks to Buy Now, 9/24/2024, According to Top Analysts
- Avidity Biosciences initiated with a Buy at Goldman Sachs
- 3 Best Stocks to Buy Now, 8/29/2024, According to Top Analysts